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Background: The most effective therapy in acute myocardial infarction (MI) is early reperfusion by percutaneous coronary intervention (PCI). 
Reperfusion limits myocardial necrosis, however induces reperfusion injury leading to additional necrosis and apoptosis. Glucagon Like Peptide-1 
(GLP-1), an incretin hormone, has anti-apoptotic properties and proved to be cardioprotective in experimental studies. This pilot study assessed the 
safety and feasibility of the GLP-1 receptor agonist exenatide in patients with acute MI undergoing primary PCI.
Methods: Seventy-one non-diabetic patients with acute MI undergoing primary PCI were randomized to placebo or exenatide 5μg bolus 
administered in 30 minutes prior to PCI, followed by continuous infusion of 20μg/ 24 hours for 72 hours. Blood samples were obtained including 
enzymatic infarct size and glucose levels. Magnetic resonance imaging and echocardiography were conducted 3-5 days and 4 months post MI for 
measurements including infarct size, cardiac function and myocardial salvage index (MSI), a predictor for mortality and major adverse cardiac 
events.
Results: Forty out of 71 randomized patients completed the full protocol. Exclusion was mainly due to angiographic criteria. Patient characteristics 
were well balanced between the groups. An equal amount of hypo- and hyperglycemic episodes (glucose < 4 mmol/L or > 10 mmol/L) were 
observed in both groups. No deaths, CABG or re-infarction occurred during the 4-month follow-up. Although more patients in the exenatide group 
experienced nausea (58% v 20%, p = 0.015), no decrease or cessation of exenatide was required. Infarct size, cardiac function and MSI at 4 months 
did not differ significantly. However, a trend towards a higher MSI was seen in patients with TIMI 0 and 1 flow receiving exenatide (0.65 ± 0.14 (n = 
12) v 0.53 ± 0.17 (n = 11), p = 0.09). 
Conclusions: We demonstrated that administering exenatide in patients with acute MI undergoing primary PCI is feasible and safe. Although not 
powered for this analysis, Exami phase l seems to show a trend towards a higher MSI in the exenatide group. A large randomized placebo controlled 
study is required to assess the efficacy of exenatide on myocardial salvage.
